GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to GlobalData, Phase II drugs for Primary Mediastinal B-Cell Lymphoma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GCC-4001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GCC-4001 overview

GCC-4001 (AB-101) is under development for the treatment of rheumatoid arthritis, systemic lupus erythematosus, pemphigus vulgaris, granulomatosis with polyangiitis and microscopic polyangiitis, B-cell non-Hodgkin lymphoma, relapsed or refractory chronic lymphocytic leukemia, diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, follicular lymphoma, Waldenstrom Macroglobulinemia, peripheral T-cell lymphomas (PTCL), angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma (ALCL), R/R classical Hodgkin lymphoma, lupus nephritis (LN) and autoimmune disorders.  The therapeutic candidate is an allogeneic, non-engineered, cord blood-derived natural killer (NK) cell therapy. It is administered through intravenous route and is being developed based on AlloNK platform.

Artiva Biotherapeutics overview

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Artiva Biotherapeutics is a biotechnology company developing allogeneic natural killer (NK) cell therapies to treat hematologic cancers or solid tumors. It is investigating AB-101, an allogeneic NK cell therapy used for the treatment of B-cell malignancies; AB-201, a CAR-NK (chimeric antigen receptor-modified natural killer) cell therapy targeting HER2 positive solid tumors; and AB-202 against CD19 positive B-cell malignancies. Artiva Biotherapeutics utilizes its proprietary CAR (chimeric antigen receptor) platform to improve NK cells’ therapeutic activity and tumor-targeting capability. Artiva Biotherapeutics is headquartered in San Diego, California, the US.

For a complete picture of GCC-4001’s drug-specific PTSR and LoA scores, buy the report here.